https://doi.org/10.55788/1152a964
Using the nationwide health registry in Denmark, Dr Mikkel Malham (Copenhagen University Hospital, Denmark) explored the association between antibiotics during the first 5 years of life and the risk of developing paediatric-onset IBD [1]. âWe still do not know exactly why some people develop paediatric-onset IBD. Early-life, environmental factors seem to play a larger role in paediatric-onset IBD than in later-onset IBD,â he explained.
The study included all patients with IBD from 1980 from the nationwide health registry in Denmark who were diagnosed <18 years of age and were followed up through 2018. These patients were matched with up to 10 healthy individuals of the same age, sex, and area of residence. Patients diagnosed before age 6 were excluded to avoid other aetiologies like monogenic causes of IBD.
Overall, 1,808 participants with paediatric-onset IBD (989 Crohnâs disease and 819 ulcerative colitis) and 17,234 matched controls were included in the analysis. Of the participants with IBD, 1,578 had at least 1 prescription of antibiotics from birth to 5 years of age compared with 14,525 prescriptions in the reference individuals.
Over time, the overall risk of developing IBD increased in participants that were prescribed antibiotics during the first 5 years (HR 1.26). âWe noticed that mainly CrohnÂŽs disease is associated with increased antibiotics prescriptions,â Dr Malham said. In addition, the risk for IBD was more pronounced in participants who had â„4 antibiotic prescriptions than in those wo did not (HR 1.43; P<0.0001). The risk for IBD also depended on the specific antibiotic that was prescribed: it was higher for broad-spectrum antibiotics compared with narrow-spectrum antibiotics.
Thus, this study confirms the critical influence of antibiotic prescriptions on the development of paediatric-onset IBD. This association underscores the importance of antibiotic stewardship in public health.
- Malham M, et al. The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 â 2018. DOP20, ECCO 2023, 01â04 March, Copenhagen, Denmark.
Posted on
Previous Article
« Proton pump inhibitors associated with worse outcomes in CD Next Article
Drop in overall IBD procedures during the pandemic »
« Proton pump inhibitors associated with worse outcomes in CD Next Article
Drop in overall IBD procedures during the pandemic »
Table of Contents: ECCO 2023
Featured articles
What Is New in Biologic Therapy?
Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD
Long-term data supports the established efficacy and safety of ustekinumab in UC
Anti-TNF withdrawal may be a safe option in stable IBD
Intensified drug therapy leads to better stricture morphology in CD
Small Molecules in IBD: State of the Art
Continued efficacy of long-term ozanimod as UC treatment
Upadacitinib successful in the management of both CD and UC
Solid results for long-term therapy of UC with filgotinib
Paediatric IBD: What You Need To Know
Perinatal period is crucial for the risk of developing CD
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Risk Factors and Complications of IBD
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Surgical Approaches: New Developments
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Pearls of the Posters
Drop in overall IBD procedures during the pandemic
Proton pump inhibitors associated with worse outcomes in CD
Poor sleep in CD linked to low levels of vitamin D
Novel AI tool assessing mucosal inflammation achieves high correlation with histopathologists
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com